Back to results
US 12,589,117 B2Granted
Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases
AssigneeExopharma, Inc.
InventorsMarilyn Glassberg Csete, Sharon Elliot, Robin Smith
Life of this patent
Estimating the term…
Abstract
The described invention provides compositions and methods for treating a fibrotic condition in a subject. The methods include administering a therapeutic amount of a pharmaceutical composition comprising synthetic extracellular vesicles (EVs) and a pharmaceutically acceptable carrier.
Claims14
A method for treating a fibrotic disease in a subject in need thereof, comprising:
- (a) obtaining a tissue sample or a body fluid sample from the subject and from a healthy control;
- (b) isolating extracellular vesicles (EVs) from mesenchymal stem cells (MSCs) derived from the tissue sample or from the body fluid sample;
- (c) measuring respective levels of expression of one or more Idiopathic Pulmonary Fibrosis (IPF) markers selected from the group consisting of integrin mRNA, collagen type 1α1 mRNA, miR29, c-jun protein;
- estrogen receptor alpha (ERα), androgen receptor (AR), caveollin-1 protein;
- pAKT/AKT protein in the EVs obtained from the subject and from the healthy control;
- (d) comparing the respective levels of expression to determine whether the level of expression of the one or more IPF markers is reduced in the subject relative to the healthy control;
- (e) in response to the one or more IPF markers being determined to be reduced in the subject relative to the healthy control, treating the subject by administering a pharmaceutical composition comprising a therapeutic amount of EVs purified from the healthy control;
- wherein the therapeutic amount is effective to modulate the level of expression of the one or more IPF markers in the urine of the subject.
5 more elements
Dependencies are inferred from the claim text.